{"schema_version":"1.0","type":"article","title":"沒有 AI 能力的藥廠，將不再被稱作藥廠","url":"https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future.md","lang":"zh-Hant","date":"2026-06-07","publish_at":"2026-06-07T10:30:00+08:00","updated_at":"2026-06-07","category":"商業分析系列","topic":"IR 與資本市場","tags":["AI","藥廠","新藥研發","製藥產業","數位轉型","商業模式"],"summary":"AI 正在從工具變成製藥公司的底層能力。未來藥廠不只比管線，也會比資料、模型、實驗自動化與決策速度，沒有 AI 能力的公司將愈來愈難被視為現代藥廠。","key_points":[],"facts":[],"sections":["01｜Google I/O 真正重要的，不是產品秀，而是科學研發的作業系統","02｜舊的新藥研發流水線，已經貴到讓整個產業喘不過氣","03｜AI 製藥不是一個工具，而是製藥業的「集裝箱」","04｜真正被衝擊的，是靠「人力試錯效率」賺錢的舊模式","05｜Big Pharma 不會等 AI 公司成熟才進場，它們已經在搶入口","06｜沒有 AI 能力的藥廠，不是明天會倒，而是估值邏輯會慢慢改變","07｜這不是 AI 取代藥廠，而是 AI 重新分層藥廠","08｜AI 製藥不是泡沫，但也不是魔法"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"New AI Tools for the Future of Science","source":"","date":"","url":""},{"title":"Gemini for Science is a new collection of science tools and experiments to expand the scale and precision of scientific exploration.","source":"","date":"","url":""},{"title":"blog.google","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"AlphaFold — Google DeepMind","source":"","date":"","url":""},{"title":"AlphaFold has revealed millions of intricate 3D protein structures, and is helping scientists understand how all of life’s molecules interact.","source":"","date":"","url":""},{"title":"deepmind.google","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"www.hpcwire.com","source":"","date":"","url":""},{"title":"https://www.hpcwire.com/2026/05/20/google-advances-ai-for-science-with-new-tools-and-tech/","source":"","date":"","url":"https://www.hpcwire.com/2026/05/20/google-advances-ai-for-science-with-new-tools-and-tech/"},{"title":"www.hpcwire.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"Isomorphic Labs announces Series B investment round  - Isomorphic Labs","source":"","date":"","url":""},{"title":"https://www.isomorphiclabs.com/articles/isomorphic-labs-announces-series-b-investment-round","source":"","date":"","url":"https://www.isomorphiclabs.com/articles/isomorphic-labs-announces-series-b-investment-round"},{"title":"www.isomorphiclabs.com","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"Alphabet's AI biotech Isomorphic Labs bags $2.1B series B","source":"","date":"","url":""},{"title":"If any proof was needed that big money is still available for AI drug development, look no further than the 10-figure series B hauled in by Isomorphic.","source":"","date":"","url":""},{"title":"www.fiercebiotech.com","source":"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-extends-partnership-with-insilico-medicine-ai-powered-drug-discovery-2026-03-30/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-extends-partnership-with-insilico-medicine-ai-powered-drug-discovery-2026-03-30/"},{"title":"www.reuters.com","source":"","date":"","url":""}],"images":[{"alt":"AI 正在把新藥研發從手工試錯推向系統化、模型化、資料化的新型研發工廠。","url":"https://drugnews.com.tw/assets/articles/pharma-ai-capability-future/dcard-01.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/pharma-ai-capability-future/dcard-01.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-07）。沒有 AI 能力的藥廠，將不再被稱作藥廠。https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-07-pharma-ai-capability-future-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}